Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 934 clinical trials
A Phase 1, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D[s]) in B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part 1 and to evaluate the

leukemia
lymphoid leukemia
beta human chorionic gonadotrophin
lymphoma
chronic lymphocytic leukemia
  • 29 views
  • 23 Oct, 2022
  • 14 locations
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL

relapsed/ refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) in Part A and to further characterize the safety at the RP2D(s) in Part B.

high dose chemotherapy
marginal zone lymphoma
cell transplantation
large b-cell lymphoma
measurable disease
  • 14 views
  • 23 Oct, 2022
  • 31 locations
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

  • 66 views
  • 07 Oct, 2022
  • 114 locations
A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

This is a Phase 1/2 study of IGM-2323 in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This study will consist of a dose-escalation stage and a randomized dose

marginal zone lymphoma
large b-cell lymphoma
measurable disease
b-cell lymphoma
ct scan
  • 43 views
  • 24 Oct, 2022
  • 13 locations
Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (ELM-2)

malignant lymphoma (Cheson, 2014) and as assessed by independent central review in each of the following B-cell non-Hodgkin lymphoma (B-NHL) subgroups: In patients with follicular lymphoma (FL

renal function
btk inhibitor
marginal zone lymphoma
alkylating agent
large b-cell lymphoma
  • 69 views
  • 07 Oct, 2022
  • 130 locations
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does …

advanced cancer
vasectomy
neutrophil count
ct scan
solid tumor
  • 200 views
  • 07 Oct, 2022
  • 126 locations
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial (CAPTUR)

Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they …

solid tumour
measurable disease
bone marrow procedure
nivolumab
lymphoma
  • 63 views
  • 27 Oct, 2022
  • 10 locations
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is

  • 5 views
  • 10 Mar, 2022
  • 7 locations
Phase 1 First in Human Study of ZN-d5 as a Single Agent

with Non-Hodgkin Lymphoma (NHL) and subjects with Acute Myeloid Leukemia (AML).

blood transfusion
leukemia
follicular lymphoma
diffuse large b-cell lymphoma
mantle cell lymphoma
  • 0 views
  • 25 Dec, 2021
  • 13 locations
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

leukemia
btk inhibitor
diffuse large b-cell lymphoma
acalabrutinib
large b-cell lymphoma
  • 0 views
  • 04 Oct, 2022
  • 45 locations